Mr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES ANNOUNCES ISSUANCE OF COMMON SHARES PURSUANT TO DEBT SETTLEMENTS, CONSULTING AGREEMENT AND EMPLOYMENT AGREEMENTS

Cognetivity Neurosciences Ltd. has entered into debt settlement agreements with certain creditors of the company to issue an aggregate of 406,773 common shares in the capital of company at a deemed price of 16 cents per debt share to settle an aggregate of approximately $24,221 of outstanding debt.

In addition, in accordance with the terms of a consulting agreement with an arm's-length consultant, the company will issue 312,500 common shares in the capital of the company at a deemed price of 16 cents per consulting share for payment of $50,000, representing work completed from March to June, 2023.

Also, in accordance with the terms of certain employment agreements, the company will issue an aggregate of 564,932 common shares in the capital of the company at a deemed price of 16 cents per service share to employees in accordance with the terms of the employment agreements.

The debt shares, consulting shares and service shares are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

Closing of the debt settlement and the issuance of consulting shares and service shares are subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, United Kingdom, Europe and the Middle East, with regulatory approval in other regions expected in 2023.

We seek Safe Harbor.